Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 5
2014 8
2015 16
2016 17
2017 14
2018 13
2019 10
2020 17
2021 25
2022 29
2023 13
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

123 results

Results by year

Filters applied: . Clear all
Page 1
Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer.
Robertson AG, Meghani K, Cooley LF, McLaughlin KA, Fall LA, Yu Y, Castro MAA, Groeneveld CS, de Reyniès A, Nazarov VI, Tsvetkov VO, Choy B, Raggi D, Marandino L, Montorsi F, Powles T, Necchi A, Meeks JJ. Robertson AG, et al. Among authors: raggi d. Nat Commun. 2023 Apr 27;14(1):2126. doi: 10.1038/s41467-023-37568-9. Nat Commun. 2023. PMID: 37105962 Free PMC article.
Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial.
Basile G, Bandini M, Gibb EA, Ross JS, Raggi D, Marandino L, Costa de Padua T, Crupi E, Colombo R, Colecchia M, Lucianò R, Nocera L, Moschini M, Briganti A, Montorsi F, Necchi A. Basile G, et al. Among authors: raggi d. Clin Cancer Res. 2022 Dec 1;28(23):5107-5114. doi: 10.1158/1078-0432.CCR-22-2158. Clin Cancer Res. 2022. PMID: 36190522 Clinical Trial.
Erdafitinib for the treatment of urothelial cancer.
Marandino L, Raggi D, Giannatempo P, Farè E, Necchi A. Marandino L, et al. Among authors: raggi d. Expert Rev Anticancer Ther. 2019 Oct;19(10):835-846. doi: 10.1080/14737140.2019.1671190. Epub 2019 Oct 4. Expert Rev Anticancer Ther. 2019. PMID: 31544541 Review.
Immunotherapy advances in uro-genital malignancies.
Ratta R, Zappasodi R, Raggi D, Grassi P, Verzoni E, Necchi A, Di Nicola M, Salvioni R, de Braud F, Procopio G. Ratta R, et al. Among authors: raggi d. Crit Rev Oncol Hematol. 2016 Sep;105:52-64. doi: 10.1016/j.critrevonc.2016.06.012. Epub 2016 Jun 17. Crit Rev Oncol Hematol. 2016. PMID: 27372200 Review.
A systematic review and meta-analysis on the optimal treatment duration of checkpoint inhibitoRS in solid tumors: The OTHERS study.
Bogani G, Cinquini M, Signorelli D, Pizzutilo EG, Romanò R, Bersanelli M, Raggi D, Alfieri S, Buti S, Bertolini F, Bonomo P, Marandino L, Rizzo M, Monteforte M, Aiello M, Tralongo AC, Torri V, Di Donato V, Giannatempo P. Bogani G, et al. Among authors: raggi d. Crit Rev Oncol Hematol. 2023 Jul;187:104016. doi: 10.1016/j.critrevonc.2023.104016. Epub 2023 May 6. Crit Rev Oncol Hematol. 2023. PMID: 37156405 Review.
123 results